KRAS Gene Mutation Analysis
KRAS is a member of the RAS family known as GTPase or GDP/GTP binding proteins playing an important role in cellular proliferation and differentiation. Due to this wide function, its mutation is found in many cancers. Although pancreatic carcinomas carry the highest frequency of KRAS mutations, KRAS mutations are also frequently seen in lung cancer such as pulmonary non-small cell carcinoma and colorectal carcinomas. In addition, KRAS mutation is also seen in gastric cancer as well as in some leukemias.
Mutated KRAS in cancer is always activated and triggers cell proliferation, which is one of the main characteristics of cancer. This makes KRAS a critical oncoprotein and tumor marker. Critical regions of oncogenic KRAS activating mutations include codons 12, 13, 59, 61, and 635-7. Any of these or a combination of these mutations (usually more than one) allow KRAS protein to accumulate in its active GTP-bound state leading to constitutive activation of downstream signaling, which then results in cell proliferation and uncontrolled cellular growth. Currently, several therapeutic drugs are used to block these steps in cancers involving KRAS signaling. However, an additional mutation or multiple mutations of the KRAS gene lead to resistance to the antitumor effect of these therapeutic agents and to upstream receptor tyrosine kinase regulators such as EGFR. In colorectal cancers, somatic KRAS mutations predominantly involve codons 12 and 13 of exon 1. Among the seven most commonly encountered mutations, six involve codon 12 and one mutation affects codon 13. The next most frequent mutation is in codon 61, which was later listed as significant and some molecular assays might not test for this mutation.
In pulmonary adenocarcinoma, somatic KRAS mutations are far more frequent in tumors that are associated with a history of cigarette smoking. The G12C mutation in codon 12 is by far the most frequent mutation in these tumors.
- KRAS mutation analysis is currently used as a predictive marker of therapy response in the setting of anti-EGFR therapy in metastatic colorectal carcinoma and pulmonary adenocarcinoma
- Anti-EGFR therapy is currently limited to tumors lacking molecular diagnostic evidence for KRAS or BRAF mutations
- As an aid in evaluation of colorectal cancer
- As an aid in evaluation of diagnosis of lung cancer
- As an aid in evaluation of pancreatic cancer
- As an aid in evaluation of colon cancer
Increased in:
- Colorectal carcinoma
- Lung carcinomas
- Pancreatic cancer (primary pancreatic adenocarcinomas)
- Breast cancer
- Gastric cancer
The presence of any of these mutations in KRAS is indicative of resistance to anti-EGFR therapies.
Negative for mutation analyzed
Formalin fixed paraffin embedded (FFPE) tumor samples. Microdissection is recommended for better sensitivity and specificity. This would increase the fraction of tumor cells in the sample as it selects for tumor cells. The presence of normal cells that carry wild type alleles can dilute the tumor cells, and dilution by normal and inflammatory cells might impact the sensitivity of mutation detection.
In colorectal cancer DNA can be also isolated from stool samples obtained from patients with colorectal cancer.
In lung cancer, sputum can be used for isolation of DNA from cancer cells.
5-10 days.
- Ann Oncol. 2011 Dec;22(12):2616-24. [PMID:22071650]
- Nat Rev Cancer. 2003 Jan;3(1):11-22. [PMID:12509763]
- Biochim Biophys Acta. 2005 Nov 25;1756(2):81-2. [PMID:16269215]
- J Clin Oncol. 2008 Jan 20;26(3):374-9. [PMID:18202412]
- J Clin Oncol. 2009 Apr 20;27(12):2091-6. [PMID:19188670]
- Arch Pathol Lab Med. 2009 Oct;133(10):1600-6. [PMID:19792050]
- Adv Anat Pathol. 2009 Jul;16(4):196-203. [PMID:19546608]
- Br J Cancer. 2007;96:1166-9. [PMID:17375050]
- J Clin Oncol. 2010 Nov 1;28(31):4769-77. [PMID:20921461]